|
US5948786A
(en)
|
1996-04-12 |
1999-09-07 |
Sumitomo Pharmaceuticals Company, Limited |
Piperidinylpyrimidine derivatives
|
|
AU2000234451B2
(en)
|
2000-03-24 |
2005-09-29 |
Asterand Uk Acquisition Limited |
Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
|
|
HN2001000224A
(es)
|
2000-10-19 |
2002-06-13 |
Pfizer |
Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
|
|
GB0031295D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Naphthalene derivatives
|
|
GB0031302D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
GB0103269D0
(en)
|
2001-02-09 |
2001-03-28 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
JP2005532291A
(ja)
|
2002-04-12 |
2005-10-27 |
ファイザー株式会社 |
抗炎症薬および鎮痛薬としてのピラゾール化合物
|
|
MXPA04009961A
(es)
|
2002-04-12 |
2004-12-13 |
Pfizer |
Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
|
|
CA2485485A1
(en)
|
2002-05-23 |
2003-12-04 |
Theratechnologies Inc. |
Antagonistic peptides of prostaglandin e2 receptor subtype ep4
|
|
CN100408570C
(zh)
|
2003-01-29 |
2008-08-06 |
阿斯特兰德英国有限公司 |
Ep4受体拮抗剂
|
|
CN1871240B
(zh)
|
2003-08-26 |
2012-11-07 |
帝人制药株式会社 |
吡咯并嘧啶酮衍生物
|
|
CA2536870C
(en)
|
2003-09-03 |
2009-10-27 |
Pfizer Inc. |
Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
|
|
US8084457B2
(en)
|
2003-09-15 |
2011-12-27 |
Lead Discovery Center Gmbh |
Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
AU2005238291A1
(en)
|
2004-05-04 |
2005-11-10 |
Pfizer Inc. |
Substituted methyl aryl or heteroaryl amide compounds
|
|
KR20070006890A
(ko)
|
2004-05-04 |
2007-01-11 |
화이자 인코포레이티드 |
오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
|
|
HN2005000795A
(es)
|
2004-10-15 |
2010-08-19 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
ATE533766T1
(de)
|
2005-05-19 |
2011-12-15 |
Merck Canada Inc |
Chinolinderivate als ep4-antagonisten
|
|
WO2006128129A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating cancer
|
|
DOP2007000068A
(es)
|
2006-04-12 |
2007-10-31 |
Sanofi Aventis Us Llc |
Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
|
|
JP5244091B2
(ja)
|
2006-04-24 |
2013-07-24 |
メルク カナダ インコーポレイテッド |
Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
|
|
CA2654811A1
(en)
|
2006-06-12 |
2007-12-21 |
Merck Frosst Canada Ltd. |
Indoline amide derivatives as ep4 receptor ligands
|
|
US20080280891A1
(en)
|
2006-06-27 |
2008-11-13 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
WO2008008059A1
(en)
|
2006-07-12 |
2008-01-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents ans uses thereof
|
|
CA2657227A1
(en)
|
2006-07-14 |
2008-01-17 |
Novartis Ag |
Pyrimidine derivatives as alk-5 inhibitors
|
|
AU2007283404B2
(en)
|
2006-08-11 |
2013-04-18 |
Merck Canada Inc. |
Thiophenecarboxamide derivatives as EP4 receptor ligands
|
|
WO2008039882A1
(en)
|
2006-09-30 |
2008-04-03 |
Sanofi-Aventis U.S. Llc |
A combination of niacin and a prostaglandin d2 receptor antagonist
|
|
CA2679175C
(en)
|
2007-02-26 |
2015-01-13 |
Merck Frosst Canada Ltd. |
Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
|
|
CN101636385B
(zh)
|
2007-03-26 |
2012-09-05 |
默克弗罗斯特加拿大有限公司 |
作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
|
|
KR20090122931A
(ko)
|
2007-03-26 |
2009-12-01 |
아스테라스 세이야쿠 가부시키가이샤 |
오르니틴 유도체
|
|
EP2014657A1
(de)
*
|
2007-06-21 |
2009-01-14 |
Bayer Schering Pharma Aktiengesellschaft |
Diaminopyrimidine als Modulatoren des EP2-Rezeptors
|
|
EP2172447A4
(en)
|
2007-07-03 |
2011-08-24 |
Astellas Pharma Inc |
amide
|
|
AU2008309517B2
(en)
|
2007-10-12 |
2013-03-14 |
Astrazeneca Ab |
Inhibitors of protein kinases
|
|
EP2254415B1
(en)
|
2008-02-19 |
2013-01-23 |
Janssen Pharmaceutica, N.V. |
Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
|
|
ES2518919T3
(es)
|
2008-05-14 |
2014-11-05 |
Astellas Pharma Inc. |
Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
|
|
US20130225528A1
(en)
|
2008-05-21 |
2013-08-29 |
Ariad Pharmaceuticals, Inc. |
Phosphorus Derivatives as Kinase Inhibitors
|
|
CN102149384B
(zh)
|
2008-08-14 |
2014-08-20 |
南京奥昭生物科技有限公司 |
作为ep4受体拮抗剂的杂环酰胺衍生物
|
|
CN102164942B
(zh)
|
2008-09-19 |
2017-02-15 |
生物科技研究有限公司 |
三萜系化合物及其使用的方法
|
|
MX2011003166A
(es)
|
2008-09-25 |
2011-04-27 |
Merck Frosst Canada Ltd |
Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
|
|
WO2011022348A1
(en)
|
2009-08-18 |
2011-02-24 |
Janssen Pharmaceutica Nv |
Ethylene diamine modulators of fatty acid amide hydrolase
|
|
CN102711757A
(zh)
|
2009-11-23 |
2012-10-03 |
莱西肯医药有限公司 |
用于治疗肠易激综合征的方法和分析法
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
WO2012039972A1
(en)
|
2010-09-21 |
2012-03-29 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition
|
|
ES2537017T3
(es)
|
2010-09-29 |
2015-06-01 |
Nb Health Laboratory Co. Ltd. |
Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
|
|
WO2012066065A1
(en)
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
Phenyl-heteroaryl amine compounds and their uses
|
|
CA2816679A1
(en)
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
3-(aminoaryl)-pyridine compounds
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
WO2012103071A2
(en)
|
2011-01-25 |
2012-08-02 |
Eisai R&D Management Co., Ltd. |
Compounds and compositions
|
|
MX2013010898A
(es)
|
2011-03-24 |
2013-12-06 |
Chemilia Ab |
Novedoso derivados de la pirimidina.
|
|
WO2012149528A1
(en)
|
2011-04-29 |
2012-11-01 |
Exelixis, Inc. |
Inhibitors of inducible form of 6-phosphofructose-2-kinase
|
|
EP2721011B1
(en)
|
2011-06-20 |
2017-09-06 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
PL2729445T3
(pl)
|
2011-07-04 |
2016-04-29 |
Rottapharm Biotech Srl |
Cykliczne pochodne aminowe jako antagoniści receptora EP4
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
WO2013090552A1
(en)
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
SG11201406584TA
(en)
|
2012-04-24 |
2014-11-27 |
Vertex Pharma |
Dna-pk inhibitors
|
|
AR091429A1
(es)
|
2012-06-29 |
2015-02-04 |
Lilly Co Eli |
Compuestos de fenoxietil piperidina
|
|
TWI572597B
(zh)
|
2012-06-29 |
2017-03-01 |
美國禮來大藥廠 |
二甲基－苯甲酸化合物
|
|
EP2711364A1
(en)
|
2012-09-21 |
2014-03-26 |
Chemilia AB |
4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
|
|
PE20151412A1
(es)
|
2012-11-27 |
2015-10-10 |
Thomas Helledays Stiftelse For Medicinsk Forskning |
Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
|
|
UA115576C2
(uk)
|
2012-12-06 |
2017-11-27 |
Байєр Фарма Акцієнгезелльшафт |
Похідні бензимідазолу як антагоністи ер4
|
|
EP2765128A1
(en)
|
2013-02-07 |
2014-08-13 |
Almirall, S.A. |
Substituted benzamides with activity towards EP4 receptors
|
|
TW201443004A
(zh)
|
2013-02-15 |
2014-11-16 |
Lilly Co Eli |
苯氧基乙氧基化合物
|
|
TWI636046B
(zh)
|
2013-05-17 |
2018-09-21 |
美國禮來大藥廠 |
苯氧基乙基二氫－１ｈ－異喹啉化合物
|
|
BR112015030095B1
(pt)
|
2013-05-30 |
2023-02-28 |
Idorsia Pharmaceuticals Ltd |
Moduladores do receptor de cxcr7
|
|
CN105431416B
(zh)
|
2013-06-12 |
2019-01-08 |
科研制药株式会社 |
4-炔基咪唑衍生物和含有其作为有效成分的药物
|
|
MX2016002544A
(es)
|
2013-09-04 |
2016-06-17 |
Squibb Bristol Myers Co |
Compuestos utiles como inmunomoduladores.
|
|
RS57508B1
(sr)
|
2013-09-06 |
2018-10-31 |
Aurigene Discovery Tech Ltd |
1,2,4-derivati oksadiazola kao imunomodulatori
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
KR102411227B1
(ko)
|
2013-10-17 |
2022-06-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
|
|
SI3057959T1
(en)
*
|
2013-10-17 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
DNA-PK INHIBITORS
|
|
JP6200596B2
(ja)
|
2013-12-17 |
2017-09-20 |
イーライ リリー アンド カンパニー |
ジメチル安息香酸化合物
|
|
HUE035698T2
(en)
|
2013-12-17 |
2018-05-28 |
Lilly Co Eli |
Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
|
|
TW201607943A
(zh)
|
2013-12-19 |
2016-03-01 |
拜耳製藥公司 |
作為ｅｐ４配體之新穎苯并咪唑衍生物
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
WO2015167825A1
(en)
|
2014-04-29 |
2015-11-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
SG11201609770TA
(en)
|
2014-05-23 |
2016-12-29 |
Eisai R&D Man Co Ltd |
Combination therapies for the treatment of cancer
|
|
CN106794181A
(zh)
|
2014-06-04 |
2017-05-31 |
托马斯·黑勒戴药物研究基金会 |
用于治疗炎性和自身免疫性病况的mth1抑制剂
|
|
CA2949793C
(en)
|
2014-06-19 |
2024-02-27 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
WO2016021742A1
(en)
|
2014-08-07 |
2016-02-11 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds as ep4 receptor antagonists
|
|
HUE052969T2
(hu)
|
2015-01-09 |
2021-05-28 |
Ono Pharmaceutical Co |
Triciklusos spiro vegyület
|
|
JP6689297B2
(ja)
|
2015-07-23 |
2020-04-28 |
武田薬品工業株式会社 |
複素環化合物
|
|
CA3002144C
(en)
|
2015-10-16 |
2024-01-23 |
Eisai R&D Management Co., Ltd. |
Ep4 antagonists
|
|
CR20180323A
(es)
|
2015-11-20 |
2018-08-06 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituídos como moduladores de los receptores de pge2
|
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
US11325899B2
(en)
|
2017-05-18 |
2022-05-10 |
Idorsia Pharmaceuticals Ltd |
Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
|
|
AR111808A1
(es)
|
2017-05-18 |
2019-08-21 |
Idorsia Pharmaceuticals Ltd |
Derivados de pirimidina como moduladores del receptor de pge2
|
|
PE20191787A1
(es)
|
2017-05-18 |
2019-12-24 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituidos
|
|
KR102612140B1
(ko)
|
2017-05-18 |
2023-12-08 |
이도르시아 파마슈티컬스 리미티드 |
피리미딘 유도체
|